+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of belimumab compared to placebo, both given alongside standard therapy, for adults with systemic sclerosis associated interstitial lung disease SSc-ILD. The study aims to assess how belimumab affects lung function and other disease features such as skin thickening and symptoms like fatigue that influence quality of life. Participants will be randomly assigned to receive either belimumab or a placebo, both in addition to their usual therapy. Belimumab is given by subcutaneous injection. The study measures various health outcomes at baseline and after 52 weeks, including lung capacity, skin condition, fatigue, and disease progression. Throughout the study, participants will undergo scans, lung function tests, skin assessments, and questionnaires about symptoms and quality of life. Researchers will monitor adverse events and disease markers to evaluate treatment impact and safety over the 52-week period.

Age: 18Years +All GendersPhase 2Phase 3
134 locations
E

Actively Recruiting

Researchers are evaluating XEN1101 as an additional treatment for people with primary generalized tonic-clonic seizures PGTCS in this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the clinical efficacy, safety, and tolerability of XEN1101 in subjects diagnosed with generalized epilepsy who are currently taking 1 to 3 anti-seizure medications ASMs. Participants must have probable or possible PGTCS and meet specific inclusion criteria. Participants aged 12 years and older will be randomly assigned to receive either XEN1101 or a placebo. Those 18 years and older will receive 25 mg of XEN1101 or placebo daily, while those between 12 and under 18 years may receive 15 mg, 25 mg, or placebo once daily with an evening meal. The study includes a baseline period lasting up to 9.5 weeks to monitor seizure frequency, followed by a 12-week double-blind treatment period. After completing this phase, participants can enter an open-label extension study to continue XEN1101 treatment or join an 8-week post-treatment follow-up. Throughout the study, participants will keep accurate seizure diaries and undergo assessments to measure the median percent change in monthly PGTCS frequency. The study will also monitor safety and tolerability during treatment. Those who do not continue into the extension phase will have follow-up visits for 8 weeks after treatment ends. Overall, the trial involves multiple visits and careful monitoring to evaluate the impact of XEN1101 as adjunctive therapy over several months.

Age: 12Years +All GendersPhase 3
141 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of a study medicine called PF-07275315 for treating adults with moderate-to-severe asthma that is not well controlled. Asthma is a condition that makes breathing difficult and affects quality of life. This phase 2 clinical trial includes participants aged 18 to 75 who have had moderate-to-severe asthma for at least 12 months and have been on maintenance asthma treatment for the past 6 months. Participants will receive either PF-07275315 or a placebo, both given as multiple subcutaneous injections in the clinic over 12 weeks. The study compares experiences between those receiving the study medicine and those receiving placebo to assess safety and effects. The trial is randomized, double-blind, and placebo-controlled with parallel groups. During the study, participants will be involved for up to approximately 9.5 months depending on local regulations. They will have regular visits for injections and assessments including lung function tests like FEV1, questionnaires about asthma control and quality of life, and safety monitoring through lab tests, vital signs, and electrocardiograms. Researchers will track changes from baseline in lung function and adverse events up to 24 weeks after treatment begins.

Age: 18Years - 75YearsAll GendersPhase 2
137 locations
S

Actively Recruiting

Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.

Age: 18Years +All GendersPhase Not Applicable
98 locations
U

Actively Recruiting

Researchers are conducting a multi-centre observational study to better understand giant cell arteritis GCA and polymyalgia rheumatica PMR, conditions mainly affecting people over 50 years old. The study aims to identify genetic factors that influence susceptibility to these diseases to provide new insights into how they develop. It includes both retrospective participants with confirmed diagnoses and prospective participants suspected of having these conditions, with some patients also enrolled in a registry monitoring tocilizumab treatment for relapsing or refractory GCA. The study collects detailed clinical, imaging, and molecular data, including genetic and proteomic analyses, from participants to characterize disease subtypes and impacts. Researchers also assess quality of life through patient-reported outcomes and track long-term prognosis by linking to health records. The study explores environmental factors and co-existing conditions to improve diagnosis, prognosis, and monitoring of disease activity, especially for patients receiving synthetic or biological disease-modifying anti-rheumatic drugs. Participants provide information during baseline assessments, including blood and urine samples for analysis, and complete questionnaires about their symptoms and quality of life. Follow-up occurs through health record review over an average of one year to evaluate diagnosis and disease outcomes. The primary measure is genetic susceptibility, with secondary outcomes focusing on disease characteristics, life impact, diagnosis, and disease activity. The study is sponsored by the University of Leeds and started in 2005, continuing through 2028.

Age: 50Years +All Genders
76 locations
S

Actively Recruiting

Researchers are investigating whether adding duroplasty, a surgical procedure that expands the tough membrane around the spinal cord, improves outcomes after severe cervical spinal cord injury. This trial focuses on adults with acute, severe injuries in the neck area who require surgery within 72 hours. The study aims to determine if duroplasty combined with standard bony decompression surgery enhances muscle strength and functional recovery compared to bony decompression alone. Participants will be randomly assigned to receive either standard spinal surgery including laminectomy alone or the same surgery plus duroplasty. Some patients may also join an optional mechanistic sub-study where probes and microdialysis catheters monitor spinal cord pressure, blood flow, metabolism, and inflammation at the injury site. The study will recruit around 222 to 260 patients over four years, including sites in the UK and internationally. During the study, participants will be assessed at baseline, 3, 6, and 12 months after surgery using questionnaires and physical examinations to measure muscle strength, hand function, walking ability, bladder and bowel control, and quality of life. Some will have MRI scans at 2 weeks and 6 months, and safety outcomes such as complications, additional surgeries, and mortality will be tracked up to 12 months. Follow-up lasts one year to evaluate recovery and treatment impact.

Age: 16Years +All GendersPhase Not Applicable
34 locations

1-10 of 23

1